Immatics N.V.
IMTXNext catalyst
IMA402
Refractory Cancer
Get an email about IMTX's next catalysts
Track Immatics (IMTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
IMTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.49 | FQ end Sep/2026 | Call: tbd
IMA402 Phase 2 Est. Readout
Estimated primary completion for IMA402 trial (NCT05958121) in Refractory Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
IMA203
Melanoma, Cutaneous Malignant
GM-CSF
Metastatic Renal Cell Carcinoma
IMA901
Metastatic Renal Cell Carcinoma
IMA901 and Leukine
Renal Cell Carcinoma
Poly ICLC
CNS Tumor, Adult
IMA402
Refractory Cancer
IMA402 and IMA401
Refractory Cancer
IMA203 product- flat dose
Refractory Cancer
IMA402 and monoclonal antibody
Refractory Cancer
IMA402 and chemotherapy +/- monoclonal antibody
Refractory Cancer
Endoxana, Leukine, IMA910, Aldara
Colorectal Carcinoma
IMA203CD8 Product
Refractory Cancer
IMA402 and checkpoint inhibitor
Refractory Cancer
IMA 950
CNS Tumor, Adult
IMA402 and chemotherapy
Refractory Cancer
IMA203 Product
Refractory Cancer
IMA970A plus CV8102 and Cyclophosphamide
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMA203 | Phase 3 | Melanoma, Cutaneous Malignant | - | - |
GM-CSF | Phase 3 | Metastatic Renal Cell Carcinoma | - | - |
IMA901 | Phase 3 | Metastatic Renal Cell Carcinoma | - | - |
IMA901 and Leukine | Phase 2 | Renal Cell Carcinoma | - | - |
Poly ICLC | Phase 2 | CNS Tumor, Adult | - | - |
IMA402 | Phase 2 | Refractory Cancer | - | - |
IMA402 and IMA401 | Phase 2 | Refractory Cancer | - | - |
IMA203 product- flat dose | Phase 2 | Refractory Cancer | - | - |
IMA402 and monoclonal antibody | Phase 2 | Refractory Cancer | - | - |
IMA402 and chemotherapy +/- monoclonal antibody | Phase 2 | Refractory Cancer | - | - |
Endoxana, Leukine, IMA910, Aldara | Phase 2 | Colorectal Carcinoma | - | - |
IMA203CD8 Product | Phase 2 | Refractory Cancer | - | - |
IMA402 and checkpoint inhibitor | Phase 2 | Refractory Cancer | - | - |
IMA 950 | Phase 2 | CNS Tumor, Adult | - | - |
IMA402 and chemotherapy | Phase 2 | Refractory Cancer | - | - |
IMA203 Product | Phase 2 | Refractory Cancer | - | - |
IMA970A plus CV8102 and Cyclophosphamide | Phase 2 | Hepatocellular Carcinoma | - | - |
Frequently asked questions
What is in Immatics N.V.'s drug pipeline?→
CatalystAlert tracks 17 drug candidates in Immatics N.V.'s (IMTX) pipeline across Phase 3, Phase 2. Its lead program is GM-CSF (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immatics N.V.'s next FDA catalyst?→
Immatics N.V.'s (IMTX) next tracked catalyst is a Phase 2 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMTX biotech catalysts?→
Add IMTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immatics N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.